Dermata Therapeutics, Inc.DRMA
Price (close)
$1.14
Market cap
$4.6M
P/E
—
Revenue (TTM)
—
Net income
-$8.4M
Dividend yield
—
1-year total return
-75.5%
Net margin
—
Revenue growth
—
Debt / equity
—
What Dermata Therapeutics, Inc. does.
to the development and commercialization of products that address common and underserved skin conditions. Dermata initially was founded
with a focus on researching and developing prescription products subject to the FDA approval process. As part of this focus, we had one
lead asset, referred to as XYNGARI, also known as DMT310, which we had been studying in clinical trials for the treatment of moderate-to-severe
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Net income | -$3.2M | -$7.9M | -$9.6M | -$7.8M | -$12.3M | -$7.6M |
More on DRMA.
- Dermata Therapeutics, Inc. summary
- Dermata Therapeutics, Inc. financial statements
- Dermata Therapeutics, Inc. key metrics
- Dermata Therapeutics, Inc. health scores and style box
- Dermata Therapeutics, Inc. earnings
- Dermata Therapeutics, Inc. dividends
- Dermata Therapeutics, Inc. valuation
- Dermata Therapeutics, Inc. ownership and insiders
- Dermata Therapeutics, Inc. peers
Figures from Dermata Therapeutics, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.